Cardiff Oncology Inc’s filing revealed that its Director PACE GARY W acquired Company’s shares for reported $41100.0 on Dec 19 ’23. In the deal valued at $1.37 per share,30,000 shares were bought. As a result of this transaction, PACE GARY W now holds 697,761 shares worth roughly $2.41 million.
William Blair initiated its Cardiff Oncology Inc [CRDF] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. H.C. Wainwright started covering the stock on October 22, 2020. It rated CRDF as “a Buy”.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock fall -1.70% to $3.46. Over the last five days, the stock has lost -22.42%. Cardiff Oncology Inc shares have risen nearly 133.78% since the year began. Nevertheless, the stocks have risen 77.44% over the past one year. While a 52-week high of $6.42 was reached on 03/25/24, a 52-week low of $0.94 was recorded on 02/05/24. SMA at 50 days reached $4.53, while 200 days put it at $2.25. A total of 1.71 million shares were traded, compared to the trading of 0.84 million shares in the previous session.
Levels Of Support And Resistance For CRDF Stock
The 24-hour chart illustrates a support level at 3.17, which if violated will result in even more drops to 2.88. On the upside, there is a resistance level at 3.69. A further resistance level may holdings at 3.92. The Relative Strength Index (RSI) on the 14-day chart is 34.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.36, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.00%. Stochastics %K at 23.26% indicates the stock is a holding.
The most recent change occurred on October 08, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $25 price target.
